^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    20h
    A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping (clinicaltrials.gov)
    P3, N=156, Not yet recruiting, Ruijin Hospital
    New P3 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    doxorubicin hydrochloride • cyclophosphamide
    22h
    Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=58, Terminated, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Terminated; Adjusted the product development strategy.
    Trial termination
    23h
    AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) (clinicaltrials.gov)
    P1/2, N=182, Recruiting, AstraZeneca | N=80 --> 182
    Enrollment change
    |
    AZD0120
    24h
    Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Suspended, University of Utah | Recruiting --> Suspended
    Trial suspension
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Tazverik (tazemetostat)
    1d
    Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia (clinicaltrials.gov)
    P1/2, N=70, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    1d
    Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT (clinicaltrials.gov)
    P3, N=218, Recruiting, Ruijin Hospital
    New P3 trial
    1d
    U96-CAR-T-Cells For R/R B-ALL (clinicaltrials.gov)
    P1, N=30, Recruiting, The First Affiliated Hospital of Soochow University
    New P1 trial
    |
    CD20 negative
    1d
    A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
    P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    golcadomide (CC-99282)
    1d
    WATCH Tranfuse: WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, University of Oxford
    New trial • HEOR
    1d
    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies (clinicaltrials.gov)
    P=N/A, N=5000, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting
    Enrollment closed
    1d
    Communication Issues in Patient and Provider Discussions of Immunotherapy (clinicaltrials.gov)
    P=N/A, N=125, Recruiting, Emory University | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    1d
    A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy (clinicaltrials.gov)
    P=N/A, N=320, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date